Annals of Oncology 5:495-505, 1994
© 1994 European Society for Medical Oncology
review-article |
Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kind
1Dept. of Medical Oncology, Rotterdam Cancer Institute Rotterdam, The Netherlands
2Dept. of Medical Oncology Centre Leon Berard, Lyon
3Dept. of Medical Oncology Centre H. Becquerel, Rouen, France
Correspondence to: J. Verweij, M.D., Ph.D., Dept. of Medical Oncology, Rotterdam Cancer Institute/Daniel den Hoed Kliniek, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Paclitaxel and docetaxel are the two presently clinically available representatives of the new class of taxane drugs. They share major parts of their structures and mechanisms of action, but differ in several other aspects. For instance, there is a difference in their tubulin polymer generation, and docetaxel appears twice as active in depolymerization inhibition. In vitro docetaxel also tends to be more potent in different cell lines and investigational models. While in vitro and in vivo studies suggest that prolonged exposure to paclitaxel is better than a brief exposure, no such tendency is seen for docetaxel, indicating it to be a schedule-independent drug. Clinical studies have not confirmed an advantage for prolonged exposure to paclitaxel; but do show differences in the toxicity profiles of the two drugs. These topics will be addressed in detail.
paclitaxel, docetaxel, taxoids
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. T. Lim, E. H. Tan, C. K. Toh, S. W. Hee, S. S. Leong, P. C. S. Ang, N. S. Wong, and B. Chowbay Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol(R)-PM) in patients with solid tumors Ann. Onc., July 24, 2009; (2009) mdp315v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Lin, H.-K. Chang, J.-S. Chen, H.-M. Wang, T.-S. Yang, and C.-C. Liaw A Phase II Randomized Study of Two Taxanes and Cisplatin for Metastatic Breast Cancer after Anthracycline: A Final Analysis Jpn. J. Clin. Oncol., January 1, 2007; 37(1): 23 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Frapolli, E. Marangon, M. Zaffaroni, T. Colombo, C. Falcioni, R. Bagnati, M. Simone, M. D'Incalci, C. Manzotti, G. Fontana, et al. Pharmacokinetics and Metabolism in Mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a New Oral C-seco-Taxane Derivative with Antiangiogenic Property Effective on Paclitaxel-Resistant Tumors Drug Metab. Dispos., December 1, 2006; 34(12): 2028 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Pino, M. Shrader, C. H. Baker, F. Cognetti, H. Q. Xiong, J. L. Abbruzzese, and D. J. McConkey Transforming Growth Factor {alpha} Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines. Cancer Res., April 1, 2006; 66(7): 3802 - 3812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hamilton and G. Hortobagyi Chemotherapy: What Progress in the Last 5 Years? J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775. [Full Text] [PDF]
|
|
|
|
|
|
K.L. Tedesco, A.D. Thor, D.H. Johnson, Y. Shyr, K.A. Blum, L.J. Goldstein, W.J. Gradishar, B.P. Nicholson, D.E. Merkel, D. Murrey, et al. Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization-Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial J. Clin. Oncol., March 15, 2004; 22(6): 1071 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Morgan Jr., J. H. Doroshow, T. Synold, D. Lim, S. Shibata, K. Margolin, R. Schwarz, L. Leong, G. Somlo, P. Twardowski, et al. Phase I Trial of Intraperitoneal Docetaxel in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: Dose-Limiting Toxicity and Pharmacokinetics Clin. Cancer Res., December 1, 2003; 9(16): 5896 - 5901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ferlini, G. Raspaglio, S. Mozzetti, M. Distefano, F. Filippetti, E. Martinelli, G. Ferrandina, D. Gallo, F. O. Ranelletti, and G. Scambia Bcl-2 Down-Regulation Is a Novel Mechanism of Paclitaxel Resistance Mol. Pharmacol., July 1, 2003; 64(1): 51 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Valero and G. N. Hortobagyi Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer? J. Clin. Oncol., March 15, 2003; 21(6): 959 - 962. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Minisini, A. Tosti, A. F. Sobrero, M. Mansutti, B. M. Piraccini, C. Sacco, and F. Puglisi Taxane-induced nail changes: incidence, clinical presentation and outcome Ann. Onc., February 1, 2003; 14(2): 333 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gedlicka, G. V. Kornek, K. Schmid, and W. Scheithauer Amelioration of docetaxel/cisplatin induced polyneuropathy by {alpha}-lipoic acid Ann. Onc., February 1, 2003; 14(2): 339 - 340. [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Hotchkiss, A. W. Ashton, R. Mahmood, R. G. Russell, J. A. Sparano, and E. L. Schwartz Inhibition of Endothelial Cell Function in Vitro and Angiogenesis in Vivo by Docetaxel (Taxotere): Association with Impaired Repositioning of the Microtubule Organizing Center Mol. Cancer Ther., November 1, 2002; 1(13): 1191 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Esteva, V. Valero, L. Pusztai, L. Boehnke-Michaud, A. U. Buzdar, and G. N. Hortobagyi Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond Oncologist, April 1, 2001; 6(2): 133 - 146. [Abstract] [Full Text]
|
|
|
|
|
|
E. Brouwer, J. Verweij, P. De Bruijn, W. J. Loos, M. Pillay, D. Buijs, and A. Sparreboom Measurement of Fraction Unbound Paclitaxel in Human Plasma Drug Metab. Dispos., October 1, 2000; 28(10): 1141 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Polizzi, G. Pratesi, S. Monestiroli, M. Tortoreto, F. Zunino, E. Bombardelli, A. Riva, P. Morazzoni, T. Colombo, M. D'Incalci, et al. Oral Efficacy and Bioavailability of a Novel Taxane Clin. Cancer Res., May 1, 2000; 6(5): 2070 - 2074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Vogel and J.-M. Nabholtz Monotherapy of Metastatic Breast Cancer: A Review of Newer Agents Oncologist, February 1, 1999; 4(1): 17 - 33. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. N. Hortobagyi Treatment of Breast Cancer N. Engl. J. Med., October 1, 1998; 339(14): 974 - 984. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Renick-Ettinger Taxotere Journal of Pediatric Oncology Nursing, January 1, 1996; 13(1): 43 - 45. [PDF]
|
|